Featured News

  • ACLA Statement on Medicare Reimbursement Rate For Serologic Testing

    May 19, 2020
    WASHINGTON, D.C. – Following the release by the Centers for Medicare and Medicaid Services (CMS) of a reimbursement rate of $42.13 for the most commonly-performed COVID-19 serologic tests, ACLA President Julie Khani released the following statement: “We applaud CMS’ release of a Medicare reimbursement rate that will encourage a broad cross section of laboratories to rapidly scale up capacity for accurate and reliable serologicContinue Reading »...
  • ACLA Statement on HEROES Act

    May 12, 2020
    WASHINGTON, D.C. — Following the introduction of the ‘‘Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act” ACLA President Julie Khani issued the following statement: “ACLA is currently reviewing the HEROES Act. As noted in our letter to Secretary Azar last month, direct federal funding for laboratories performing COVID-19 testing is critical to achieve our nation’s testing goals. As labs across the country plan for the large capital expensesContinue Reading »...
  • ACLA Statement on Expanding Access to Testing

    May 11, 2020
    WASHINGTON, D.C. — Following the Trump Administration’s announcements today on expanding access to testing, ACLA President Julie Khani released the following statement:  “After scaling up to meet an unprecedented demand for testing, ACLA members have performed nearly five million tests for COVID-19. By expanding the availability of specimen collection materials, such as swabs and transport media, the actions announced by the White House today will help states takeContinue Reading »...
  • ACLA Statement on FDA’s Revised Policy for Serologic Tests  

    May 04, 2020
    WASHINGTON, D.C. –  Following the revised policy on serologic testing announced today by the Food and Drug Administration, ACLA President Julie Khani issued the following statement: “ACLA is reviewing the latest announcement by the FDA. We commend the agency for its continued diligence in evaluating the available data regarding testing options and implementing policies that promote the public’s health. It is essential that patients and clinicians canContinue Reading »...
  • ACLA Statement on White House Meeting

    April 27, 2020
    WASHINGTON, D.C. – Following today’s meeting at the White House, ACLA President Julie Khani issued the following statement: “ACLA appreciated the opportunity to meet today with President Trump, Vice President Pence and other members of the White House Coronavirus Task Force. Representing the backbone of our nation’s testing response, ACLA members have now performed 3.2 million tests and remain focused on continuing to increaseContinue Reading »...
  • ACLA Statement on the Paycheck Protection Program and Health Care Enhancement Act

    April 22, 2020
    WASHINGTON, D.C. — Following Senate passage of the Paycheck Protection Program and Health Care Enhancement Act, ACLA President Julie Khani released the following statement: ACLA commends Congress for recognizing the need to substantially increase funding and support for testing in the most recent COVID-19 legislative package. This is an important step to provide states, federal agencies and the clinical laboratory community with the resourcesContinue Reading »...
  • Clinical Labs Support Congressional Funding To Ensure Robust Testing Infrastructure

    April 20, 2020
    Federal Funding Is Needed To Ensure Laboratories Can Scale High Throughput Testing For COVID-19 Washington, D.C. – The American Clinical Laboratory Association is encouraged by reports from Congressional leaders and the Administration regarding $25 billion in funding for COVID-19 testing. Moving forward, it is critical that any funding includes robust support for commercial laboratories performing and expanding COVID-19 testing, including high throughput tests thatContinue Reading »...
  • Dave King joins ACLA as Special Advisor

    April 20, 2020
    WASHINGTON, D.C. — The American Clinical Laboratory Association (ACLA) today announced Dave King, former CEO of Laboratory Corporation of America Holdings (LabCorp), will join ACLA as a special advisor. Building on his twenty years of service to the industry, including more than a decade serving on the ACLA board, King will support the association’s strategic and tactical responses to the COVID-19 pandemic. In this role,Continue Reading »...
  • As Nation Recognizes Laboratory Professionals Week, ACLA Highlights Extraordinary Efforts of “The Laboratory People”

    April 19, 2020
    Association announces plans to highlight members’ efforts during Laboratory Professionals Week (April 19 – 25) WASHINGTON, D.C. — Today, the American Clinical Laboratory Association (ACLA) announced plans to highlight stories of laboratory researchers, technicians, administrative staff, and medical officers who are going above and beyond the call of duty to serve patients during the COVID-19 pandemic. “Tens of thousands of laboratory staff are workingContinue Reading »...
  • CMS Takes Decisive Action to Support Laboratories Responding to COVID-19 Pandemic

    April 15, 2020
    WASHINGTON, D.C. – Following the decision announced today by Centers for Medicare & Medicaid Services (CMS) to raise the Medicare reimbursement rate for high throughput COVID-19 molecular tests from about $51 to $100 dollars, ACLA President Julie Khani issued the following statement: “In an acknowledgement of the considerable strain that has been placed on clinical laboratories supporting our nation’s response to the COVID-19 pandemic,Continue Reading »...